Angelica sinensis for Health & Longevity - Quick Reference Sheet

Angelica sinensis for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Angelica sinensis is a Chinese medicinal root supplement used orally for menopausal comfort, circulation, and kidney preservation. In chronic kidney disease, oral use is linked to lower kidney failure and death, yet alone it alters neither sex hormones nor hot flashes; other benefits rely on multi-herb formulas or injections. Trials show good tolerance, though warfarin blood thinning, liver injury, breast cell growth, and species substitution remain key considerations. (Full Review)

Protocol

Standard oral root monotherapy
1,000–4,500 mg/day
1,000 mg/day granulated extract up to 4,500 mg/day root in clinical trials; 3,000–15,000 mg/day in decoctions
Synergistic Danggui Buxue Tang protocol
3,000–7,500 mg/day (1:5 ratio)
Angelica sinensis plus Astragalus membranaceus (1:5): 3,000 mg/day for hot flashes or 7,500 mg/day for endurance recovery
Single versus split dosing and timing
2–3 divided doses with meals
Split across morning, midday, and evening meals due to rapid ferulic acid and phthalide clearance
Time to effect
Renal Preservation and Survival in Chronic Kidney Disease
>30–90 days
Cumulative oral exposure (>30–90 defined daily doses) for CKD renoprotection (45% lower mortality, 23% lower ESRD risk)
Menopausal and Hormonal Vasomotor Symptom Relief
4–12 weeks
Multi-herb vasomotor relief only (90–96% hot flush reduction at 12 weeks); oral monotherapy shows no effect over 24 weeks
Erythropoiesis, Iron Homeostasis, and Aerobic Recovery
11 days
Exercise iron mobilization (+63.3% post-exercise serum iron) and 14.0% faster 13-km run with Danggui Buxue Tang

Benefits

Contraindications
  • Pregnant and breastfeeding women
  • Individuals with hormone-sensitive malignancies or conditions (estrogen-receptor-positive breast, endometrial, or ovarian cancer, endometriosis, uterine fibroids)
  • Patients scheduled for elective surgery (washout at least 2 weeks prior to surgery) or with active bleeding disorders
  • Individuals with active liver injury or decompensated cirrhosis
Key Interactions
  • Vitamin K antagonist anticoagulants (warfarin, acenocoumarol; INR check within 5–7 days if co-administered)
  • Antiplatelet agents (aspirin, clopidogrel, ticagrelor)
  • Direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran) and heparins (enoxaparin) (theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs; ibuprofen, naproxen) and selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine) (theoretical)
  • Selective estrogen receptor modulators (SERMs; tamoxifen, raloxifene) and aromatase inhibitors (AIs; letrozole, anastrozole) (theoretical)
  • Cytochrome P450 CYP2D6 and CYP3A4 substrates (metoprolol, midazolam, atorvastatin) and CYP1A2 substrates (caffeine, theophylline) (theoretical)
  • Anticoagulant or antiplatelet supplements (Ginkgo biloba, Panax ginseng, garlic, Salvia miltiorrhiza, EPA/DHA) (theoretical)
  • Photosensitizing agents and ultraviolet light therapy (Hypericum perforatum [St. John's wort], doxycycline, isotretinoin) (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Anticoagulant potentiation and bleeding risk; mild gastrointestinal symptoms; herb-induced liver injury; gynecomastia and estrogenic tissue stimulation; local cutaneous burning and mild pain; transient blood pressure elevation
  • Speculative: Furocoumarin-mediated photosensitivity and phototoxicity; hormone-receptor-positive breast cancer cell proliferation

Monitoring

Marker Target Why
eGFR ≥90 mL/min/1.73 m² (standard reference range) Expected-change marker: tracks renal preservation and CKD slope (calculated from fasting serum creatinine and cystatin C)
Hemoglobin & Serum Iron Hemoglobin: 13.5–17.5 g/dL men, 12.0–15.5 g/dL women; Serum iron: 60–170 μg/dL (standard reference range) Expected-change marker: evaluates blood-building and iron-mobilizing response (paired with serum ferritin and transferrin saturation)
ALT & AST ALT: 7–56 U/L; AST: 8–33 U/L (standard reference range) Safety check: detects idiosyncratic herb-induced liver injury (discontinuation threshold >3× upper limit of normal)
PT / INR INR 0.8–1.1 (standard reference range; or prescribed target on warfarin) Safety check: detects anticoagulant potentiation when co-administered with vitamin K antagonists
Blood Pressure No established target; change from individual baseline Safety check: screens for rare transient blood pressure elevation

Cadence: At baseline, at 4 weeks for liver transaminases (ALT/AST) and iron/hematology markers, and every 3–6 months during ongoing supplementation; seated resting blood pressure at baseline and during the first 2 weeks; PT/INR within 5–7 days of starting or stopping if co-administered with warfarin.

Qualitative Assessment

  • Vasomotor symptom diary: Daily hot-flash and night-sweat frequency with multi-herb formulas.
  • Aerobic recovery: Post-exercise exertion and pace recovery.
  • Tolerance: Bruising, gingival bleeding, eructation (belching), or dark urine.